Dr. Shore on Benefits of Immunotherapy INO-5150 in Recurrent Prostate Cancer

​

Neal D. Shore, MD, FACS, medical director of the Carolina Urologic Research Center, discusses the potential benefits of the immunotherapy INO-5150 for patients with biochemically recurrent prostate cancer.

In a phase 1/2, open-label, multicenter study enrolled patients with biochemically recurrent prostate cancer and treated them with INO-5150, a DNA-based immunotherapy. This agent targets prostate-specific antigen and prostate-specific membrane antigen and was previously examined with or without plasmid-encoded cytokine adjuvant IL-12 (INO-9012). When it comes to recurrent prostate cancer, it is important to have options available, says Shore. Now, patients may have the option of receiving a daily pill rather than a required intramuscular or subcutaneous injection. This route of administration allows for patients to avoid a mandated trip to the hospital to receive the therapy, along with all the risks associated with COVID-19. 

The ability to take a once-daily pill is very convenient for patients, adds Shore. When a clinical evaluation is appropriate, then patients can met with their urologist, medical oncologist, or radiation oncologist. Overall, this kind of option provides patients with tremendous flexibility, and thus, it is a breakthrough in the treatment armamentarium for this patient population, concludes Shore.